Related Experiment Video
Updated: Sep 26, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
Zhanpeng Ou1, Ling Qiu1, Haixu Rong1
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Background:
Chimeric antigen receptor (CAR)-based immunotherapy has shown great potential for the treatment of both hematopoietic malignancies and solid tumors. Nevertheless, multiple obstacles still block the development of CAR-based immunotherapy in the clinical setting. In this study, we aimed to summarize the research landscape and highlight the front lines and trends of this field.
Methods:
Literature published from 2001 to 2021 was searched in the Web of Science Core Collection database. Full records and cited references of all the documents were extracted and screened. Bibliometric analysis and visualization were conducted using CiteSpace, Microsoft Excel 2019, VOSviewer and R software.
Results:
A total of 5981 articles and reviews were included. The publication and citation results exhibited increasing trends in the last 20 years. Frontiers in Immunology and Blood were the most productive and most co-cited journals, respectively. The United States was the country with the most productive organizations and publications in the comprehensive worldwide cooperation network, followed by China and Germany. June, C.H. published the most papers with the most citations, while Maude, S.L. ranked first among the co-cited authors. The hotspots in CAR-based therapy research were multiple myeloma, safety and toxicity, solid tumors, CAR-engineered immune cells beyond T cells, and gene editing.
Conclusion:
CAR-based immunotherapy is a promising treatment for cancer patients, and there is an emerging movement toward using advanced gene modification technologies to overcome therapeutic challenges, especially in solid tumors, and to generate safer and more effective universal CAR-engineered cell products.
Insights
Chimeric antigen receptor (CAR)-based immunotherapy shows promise for treating cancers. Research trends highlight overcoming challenges in solid tumors and developing safer CAR-engineered cell products for enhanced cancer treatment.
Area of Science:
- Immunotherapy
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-based immunotherapy demonstrates significant potential for treating both blood cancers and solid tumors.
- Clinical development of CAR-based immunotherapy faces several persistent obstacles.
- This study aims to map the research landscape and identify key trends in CAR-based immunotherapy.
Purpose of the Study:
- To summarize the research landscape of CAR-based immunotherapy.
- To highlight the front lines and emerging trends in the field.
- To identify key research areas and influential contributors.
Main Methods:
- Bibliometric analysis of literature published from 2001 to 2021 from the Web of Science Core Collection.
- Data extraction and screening of full records and cited references.
- Visualization and analysis using CiteSpace, Microsoft Excel 2019, VOSviewer, and R software.
Main Results:
- A total of 5981 articles and reviews were analyzed, showing increasing publication and citation trends over 20 years.
- The United States led in publications and collaborations, with China and Germany also being significant contributors.
- Key research hotspots include multiple myeloma, safety and toxicity, solid tumors, CAR-engineered non-T cells, and gene editing.
Conclusions:
- CAR-based immunotherapy is a promising cancer treatment modality.
- Advanced gene modification technologies are crucial for overcoming therapeutic challenges, particularly in solid tumors.
- The field is moving towards developing safer, more effective universal CAR-engineered cell products.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...